Form 4: DocGo Director Klasko Granted 100,000 RSUs

DocGo Inc. Director Stephen K. Klasko, M.D. was granted 100,000 restricted stock units, vesting in September 2026.

Summary

• Stephen K. Klasko, M.D., a Director of DocGo Inc. (DCGO), was granted 100,000 restricted stock units (RSUs).
• The grant occurred on September 10, 2025, with a transaction price of $0.
• These RSUs are part of the Issuer's 2021 Stock Incentive Plan.
• Each RSU represents the right to receive one share of Common Stock upon vesting.
• The RSUs are scheduled to vest on September 10, 2026.
• Following this transaction, Dr. Klasko beneficially owns 115,000 shares of Common Stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive signal for aligning interests and retention, but it's a routine compensation event rather than a major strategic announcement.

Positives

• Grant of 100,000 Restricted Stock Units (RSUs) to a Director, aligning management's interests with shareholders.
• The RSUs vest over a future period (September 10, 2026), indicating a retention incentive for key personnel.

Risks

• The RSUs are subject to vesting conditions, meaning the shares are not immediately owned and could be forfeited if conditions are not met (e.g., continued employment until September 10, 2026).

Future Outlook

The grant of Restricted Stock Units with a future vesting date (September 10, 2026) indicates an expectation of continued service from the director and aligns their long-term interests with the company's performance.

Industry Context

Equity grants like RSUs are a common form of executive and director compensation in the healthcare technology and mobile health sectors, aiming to incentivize long-term performance and retention.

Comparison to Industry Standards

• Granting Restricted Stock Units (RSUs) to directors is a standard practice in publicly traded companies, including those in the healthcare technology sector, such as Teladoc Health (TDOC) or Amwell (AMWL), to align director interests with shareholder value creation.
• The vesting schedule, while not explicitly detailed beyond the vesting date, is typical for retention and performance incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of a director's interests with long-term company performance.
• Management: Strengthens retention and incentivizes long-term commitment from a key director.

Next Steps

• The 100,000 Restricted Stock Units are scheduled to vest on September 10, 2026, at which point they will convert into shares of Common Stock, subject to the terms of the 2021 Stock Incentive Plan.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice aimed at aligning interests and retaining talent. It does not provide new information that would fundamentally alter the investment thesis for DocGo Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

DocGo, DCGO, Stephen K. Klasko, Restricted Stock Units, RSUs, Insider Trading, Form 4, Stock Grant, Director Compensation